April 13, 2022
More than 280 million people suffer from depression worldwide, with many not responding to conventional treatments, and over 5,000 lives
April 6, 2022
Psilocybin was first isolated in 1958 by Albert Hofmann and is one of the most researched psychedelic medicines, with over
March 30, 2022
At the end of 2021, UK-based COMPASS Pathways shared positive results from its Phase IIb clinical trial of COMP360 psilocybin
March 23, 2022
Acceleration the adoption and accessibility of psychedelic healthcare is crucial to drive innovation in mental health care and improved patient
March 16, 2022
At the PSYCH Symposium on 11 May, industry leaders will connect and collaborate to expedite access to psychedelic-based healthcare across
March 9, 2022
Novamind today announced it has been contracted by the Usona Institute to provide a research site for its Phase II
March 1, 2022
It is estimated 15 million people suffer from PTSD each year, with wide-reaching socioeconomic consequences. Many of those afflicted are
February 22, 2022
Patenting psychedelic medicines, delivery technologies and treatment paradigms provides manufacturers with a period of market exclusivity, incentivising innovation by enabling
February 16, 2022
PSYCH Symposium: London 2022 will take place at the prestigious National Gallery on Wednesday, 11 May – unlocking the potential
February 9, 2022
Cybin is conducting clinical trials with a number of tryptamines to treat a plethora of disorders. Today it was awarded
February 2, 2022
Psychedelic profiles LSD Lysergic acid diethylamide is a synthetic serotonergic psychedelic. It binds to both serotonin and dopamine receptors, in
January 26, 2022
Psychedelic profiles ibogaine Ibogaine is a psychoactive compound found in several plants, most notably in the roots of the iboga
